Cart
sales@molnova.com
Methenolone enanthate
CAS No. 303-42-4
Methenolone enanthate( —— )
Catalog No. M24230 CAS No. 303-42-4
Methenolone enanthate is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of anemia due to bone marrow failure.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 56 | In Stock |
|
| 25MG | 116 | In Stock |
|
| 50MG | 177 | In Stock |
|
| 100MG | 262 | In Stock |
|
| 200MG | 375 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMethenolone enanthate
-
NoteResearch use only, not for human use.
-
Brief DescriptionMethenolone enanthate is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of anemia due to bone marrow failure.
-
DescriptionMethenolone enanthate is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of anemia due to bone marrow failure.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number303-42-4
-
Formula Weight414.62
-
Molecular FormulaC27H42O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCCCCCC(O[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC[C@H]1C3)[C@H]2[C@@]1(C)C(C)=CC3=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
N-CBZ-Phe-Arg-AMC hy...
N-CBZ-Phe-Arg-AMC hydrochloride (N-CBZ-Phe-Arg-AMC hydrochloride (65147-22-0 Free base)) is a cysteine peptidase and serine protease substrate that can be used to assess cysteine peptidase and serine protease activity.
-
Serotonin creatinine...
Serotonin creatinine sulfate complex is a neurotransmitter.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
